Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 24, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on July 24, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 820 Common Stock at $528.72 ($433,549) on July 24, 2026; holds 333,123 after (Indirect).
- Open-market sale: disposed of 2,285 Common Stock at $530.45 ($1,212,080) on July 24, 2026; holds 330,838 after (Indirect).
- Open-market sale: disposed of 1,115 Common Stock at $531.10 ($592,179) on July 24, 2026; holds 329,723 after (Indirect).
- Open-market sale: disposed of 2,719 Common Stock at $532.27 ($1,447,229) on July 24, 2026; holds 327,004 after (Indirect).
- Open-market sale: disposed of 1,818 Common Stock at $533.20 ($969,356) on July 24, 2026; holds 325,186 after (Indirect).
- Open-market sale: disposed of 630 Common Stock at $534.39 ($336,668) on July 24, 2026; holds 324,556 after (Indirect).
- Open-market sale: disposed of 113 Common Stock at $535.03 ($60,458) on July 24, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on July 24, 2026; holds 274,910 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,051,519 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-24 | Option exercise/conversion | Common Stock | 9,500 | $135 | $1.3M | 333,943 |
| 2026-07-24 | Open-market sale | Common Stock | 820 | $529 | $433.5K | 333,123 |
| 2026-07-24 | Open-market sale | Common Stock | 2,285 | $530 | $1.2M | 330,838 |
| 2026-07-24 | Open-market sale | Common Stock | 1,115 | $531 | $592.2K | 329,723 |
| 2026-07-24 | Open-market sale | Common Stock | 2,719 | $532 | $1.4M | 327,004 |
| 2026-07-24 | Open-market sale | Common Stock | 1,818 | $533 | $969.4K | 325,186 |
| 2026-07-24 | Open-market sale | Common Stock | 630 | $534 | $336.7K | 324,556 |
| 2026-07-24 | Open-market sale | Common Stock | 113 | $535 | $60.5K | 324,443 |
| 2026-07-24 | Option exercise/conversion | Stock Option | 9,500 | — | — | 274,910 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-24 | Option exercise/conversion (9,500 shares) |
| 2026-07-24 | Open-market sale (820 shares) |
| 2026-07-24 | Open-market sale (2,285 shares) |
| 2026-07-24 | Open-market sale (1,115 shares) |
| 2026-07-24 | Open-market sale (2,719 shares) |
| 2026-07-24 | Open-market sale (1,818 shares) |
| 2026-07-24 | Open-market sale (630 shares) |
| 2026-07-24 | Open-market sale (113 shares) |
| 2026-07-24 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.